VERDUGO HILLS HOSPITAL
1. Target Overview & Investment Thesis
VERDUGO HILLS HOSPITAL is a 134-bed under-performing / distressed in LOS ANGELES, CA with $162.4M in net patient revenue and a -14.5% operating margin. The hospital serves a payer mix of 40.9% Medicare, 4.3% Medicaid, and 54.8% commercial.
Thesis: Undervalued. Our ML models identify $12.0M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -14.5% to -7.1% (+736bps).
| Net Revenue HCRIS | $162.4M |
| Current EBITDA COMPUTED | $-23.5M |
| Operating Margin COMPUTED | -14.5% |
| Occupancy HCRIS | 46.0% |
| Revenue / Bed COMPUTED | $1.2M |
| Net-to-Gross HCRIS | 17.1% |
| Distress Probability ML | 48.3% |
2. Market Context & Competitive Position
CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of -14.5% places it below the state median. Among 193 size-comparable peers (67-268 beds), the median margin is -3.6%. The target's below-peer margin suggests operational improvement opportunity.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (67-268), prioritizing same-state peers. 193 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| VERDUGO HILLS HOSPITAL (Target) | CA | 134 | $162.4M | -14.5% |
| CITY OF HOPE NATIONAL MEDICAL | CA | 217 | $1.83B | -10.7% |
| ENLOE MEDICAL CENTER | CA | 258 | $834.4M | -0.5% |
| KFH - SOUTH SACRAMENTO | CA | 233 | $803.9M | 5.9% |
| COMMUNITY HOSP. MONTEREY PENIN | CA | 227 | $797.2M | 9.3% |
| KFH - MANTECA | CA | 213 | $796.8M | 15.2% |
| LAC OLIVE VIEW/UCLA MEDICAL CE | CA | 225 | $754.9M | -10.5% |
| MARIAN MEDICAL CENTER | CA | 252 | $751.5M | 4.7% |
| KFH - SAN FRANCISCO | CA | 239 | $734.9M | 2.6% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $12.0M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $3.4M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $3.2M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $3.2M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $2.0M | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $104K | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $-23.5M |
| + RCM Uplift | +$12.0M |
| Pro Forma EBITDA | $-11.5M |
| Current Margin | -14.5% |
| Pro Forma Margin | -7.1% |
| WC Released (1x) | $6.2M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $-36.1M | $-35.4M | 0.00x | -100.0% |
| Base (11x exit) | 10.0x | 11.0x | $-36.1M | $-50.7M | 0.00x | -100.0% |
| Bull Case | 9.0x | 11.0x | $-32.5M | $-23.0M | 0.00x | -100.0% |
| Bull (12x exit) | 9.0x | 12.0x | $-32.5M | $-34.7M | 0.00x | -100.0% |
| Bear Case | 11.0x | 10.0x | $-39.8M | $-83.4M | 0.00x | -100.0% |
| Bear (11x exit) | 11.0x | 11.0x | $-39.8M | $-104.7M | 0.00x | -100.0% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| High | Negative operating margin | RCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion |
| Low | Low net-to-gross ratio | Large contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 193 hospitals with 67-268 beds
- Same-state prioritization (n=194)
- Comp margins: P25=-18.1% / P50=-3.6% / P75=4.8%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.